skip to the content

Clinical Trials

Malignant Brain Tumor Study

PBMTC ONC-032P: High Dose Temozolomide, Thiotepha and Carboplatin with autologous stem cell rescue followed by continuation therapy with 13-CIS-Retinoic Acid in patients with r ecurrent/refractory Malignant Brain Tumors

Protocol ID

05.10.115

Protocol Description

The current standard treatment for children with recurrent brain tumors has been standard dose chemotherapy. The tumor responds by shrinking, but typically returns again in months. A drug called 13-cis-retinoic acid has been used in other types of pediatric cancers and research is just beginning to use it for treatment of recurrent brain tumors. In this study, researchers want to give patients 13-cis-retinoic acid for 6 months after they recover from high dose chemotherapy with stem cell rescue.

The purpose of this study is to:  

  • Find out what effects (good and/or bad) treatment with high dose temozolomide, thiotepa and carboplatin with a stem cell rescue followed by 13-cisretinoic acid has on children and adolescents with recurrent/refractory brain tumors
  • Find out how the body uses 13-cisretinoic acid by studying the patient’s blood levels and proteins in the blood that break down the 13-cisretinoic acid
  • Determine how well 13-cisretinoic acid penetrates into the spinal fluid as it may be less effective if it cannot cross well into the central nervous system and reach the medulloblastoma cells.

Eligibility Criteria

Children with brain tumors

Primary Investigator(s)

  • Mark Atlas, MD

Contact Information

Alyssa Quinlan, PA-C
(718) 470-4356
aquinlan1@nshs.edu

Last Update

March 29, 2010
top
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Children's Health:
top
top